Answers are grounded in this paper and cite their sources.
which reduces TGFβ isomers (TGFβ1 and TGFβ2) thereby reducing cancer inhibition of the targeted immune response. Results generated to date justify advancement to confirmatory clinical trials supporting product regulatory approval.
No takes yet. Share an insight, caveat, or question.
Nemunaitis et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: